1. Home
  2. GCTK vs GRI Comparison

GCTK vs GRI Comparison

Compare GCTK & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GlucoTrack Inc.

GCTK

GlucoTrack Inc.

HOLD

Current Price

$1.58

Market Cap

1.6M

Sector

Health Care

ML Signal

HOLD

Logo GRI Bio Inc.

GRI

GRI Bio Inc.

HOLD

Current Price

$2.49

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCTK
GRI
Founded
2001
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6M
1.9M
IPO Year
2011
2020

Fundamental Metrics

Financial Performance
Metric
GCTK
GRI
Price
$1.58
$2.49
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$644.00
AVG Volume (30 Days)
205.9K
338.7K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
17910.53
N/A
EPS
30.09
N/A
Revenue
$589,462.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.05
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.09
$0.18
52 Week High
$15.90
$11.12

Technical Indicators

Market Signals
Indicator
GCTK
GRI
Relative Strength Index (RSI) 25.95 53.72
Support Level $1.52 $1.21
Resistance Level $4.24 $2.87
Average True Range (ATR) 0.13 0.23
MACD 0.07 -0.09
Stochastic Oscillator 24.48 52.73

Price Performance

Historical Comparison
GCTK
GRI

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

Share on Social Networks: